Amarin Corporation plc , has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for its US Patent Applications Serial Numbers 13/458,496 and 13/349,157.
The allowed '496 and '157 applications continue to broaden our claimed methods of reducing triglycerides consistent with the FDA approved MARINE indication for Vascepa capsules through use of a pharmaceutical composition of highly pure icosapent ethyl, or EPA.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030. After issuance, Amarin plans to list these patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
"The issuance of these Notices of Allowance further strengthens Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's chairman and chief executive officer. "Amarin now has 15 patents either issued or allowed that position Vascepa for exclusivity to 2030 and beyond."
Amarin now has 15 US patents either issued or allowed and over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.